The effects of angiotensin-converting enzyme inhibitors in heart recipients: a single center experience

The effects of angiotensin-converting enzyme inhibitors in heart recipients: a single center experience

Aim. To study the effect of ACE inhibitors (ACEI) in heart recipients on the prognosis and myocardial remodeling.Materials and methods. Three hundred and eighty-six patients who received orthotopic heart transplantation (HT) were consequently enrolled to the study from February 2009 to November 2016...

Full description

Saved in:

Bibliographic Details
Main Authors:	А. О. Shevchenko, R. A. Faradzhov, D. A. Izotov, N. N. Koloskova, Е. A. Nikitina, O. E. Gichkun, V. I. Orlov, I. Yu. Tunyaeva, B. L. Mironkov
Format:	Article
Language:	Russian
Published:	Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov 2019-01-01
Series:	Вестник трансплантологии и искусственных органов
Subjects:	heart transplantation angiotensinconverting enzyme inhibitors survival myocardial remodeling
Online Access:	https://journal.transpl.ru/vtio/article/view/945
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The use of angiotensin-converting enzyme inhibitors in general medicine
by: M.L.I. Mashitisho
Published: (2012-08-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

The role of the classical renin–angiotensin system and angiotensin-converting enzyme 2/Ang(1–7)/Mas axis in pulmonary fibrosis
by: Changhui Lang, et al.
Published: (2025-07-01)

Angiotensin Converting Enzyme Inhibitors: Interaction Issues in Patients with Glaucoma and Arterial Hypertension. Review
by: S. I. Makogon, et al.
Published: (2023-12-01)

The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitus
by: O. K. Vikulova, et al.
Published: (2020-08-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

An angiotensin-converting enzyme inhibitor in the combination treatment of rheumatoid arthritis
by: E. B. Komarova, et al.
Published: (2017-09-01)

IMPACT OF ANGIOTENSIN-CONVERTING ENZYME GENE POLYMORPHISM ON THE DEVELOPMENT OF INSULIN RESISTANCE SYNDROME
by: G. E. Roitberg, et al.
Published: (2014-07-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN ACUTE MYOCARDIAL INFARCTION: WHEN TO START THERAPY AND WHICH DRUG TO USE?
by: S. Y. Martsevich, et al.
Published: (2015-12-01)

THE CAPABILITIES OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CLINICAL PRACTICE: FOCUS ON VASOPROTECTION
by: D. B. Nebieridze, et al.
Published: (2015-12-01)

Effect of renin-angiotensin -aldosterone system blockers on myocardial remodeling processes and risk for atrial fibrillation in patients with arterial hypertension
by: O. M. Drapkina, et al.
Published: (2014-07-01)

Angiotensin II and COVID-19. Secrets of interactions
by: A. O. Konradi, et al.
Published: (2020-05-01)

ADVANTAGES OF COMBINATION THERAPY OF HYPERTENSION WITH CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IN PATIENTS WITH IMPAIRED RENAL FUNCTION
by: N. A. Dzhaiani
Published: (2015-09-01)

THE USE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AFTER MYOCARDIAL INFARCTION. WHAT DO EVIDENCE-BASED MEDICINE DATA SPEAK FOR?
by: S. Yu. Martsevich
Published: (2016-01-01)

SARTANS AND ANGIOTENSIN CONVERTING ENZYME INHIBITORS: A DUEL BETWEEN TWO LEADERS OF PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES
by: K. A. Gyamdzhyan, et al.
Published: (2015-12-01)

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in older adults with type 2 diabetes mellitus: a target trial emulation study
by: Weihong Zeng, et al.
Published: (2025-05-01)

Role of angiotensin-converting enzyme inhibitors in reducing cardiovascular and cerebral complications in chronic kidney disease: focus perindopril
by: I. T. Murkamilov
Published: (2021-01-01)

Quantitative structure-activity relationship study of some angiotensin-converting enzyme inhibitor drugs in the treatment of hypertension based on Monte Carlo optimization method
by: Shahram Lotfi, et al.
Published: (2025-05-01)

COMBINATION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND CALCIUM CHANNEL BLOCKERS IN HYPERTENSIVE PATIENTS WITH HEART FAILURE AND PRESERVED SYSTOLIC FUNCTION: IS THERE A PLACE FOR AN INFORMED CHOICE?
by: I. V. Zhirov, et al.
Published: (2013-12-01)

Polymorphisms of angiotensin converting enzyme,angiotensinogen and endothelial nitric oxide synthase gene in IgA nephropathy in Xinjiang Uygur
by: SONG Xue, et al.
Published: (2017-01-01)

Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer – New Scientific Evidences or Another Example of “Pseudo-Evidence” Medicine?
by: S. Yu. Martsevich
Published: (2019-01-01)

INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?
by: S. V. Stolov
Published: (2020-12-01)

SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW
by: S. R. Gilyarevskiy, et al.
Published: (2016-01-01)

Fabrication, characterization, antihypertensive effect and potential mechanisms of a novel angiotensin Ⅰ-converting enzyme inhibitory peptide derived from garlic by-products
by: Xiang Lu, et al.
Published: (2025-07-01)

IS IT WORTH TO DISCONTINUE DRUGS BLOCKING THE ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE PERI-OPERATIVE PERIOD?
by: V. V. Lomivorotov, et al.
Published: (2018-07-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND ACE INHIBITORS: OPTIMIZATION OF CHOICE FOR TREATMENT OF CARDIOVASCULAR DISEASES
by: E. M. Khurs, et al.
Published: (2016-01-01)

Heart and pulmonary artery remodeling association with various levels of natriuretic peptides and renin-angiotensin-aldosterone system activation in patients with pulmonary hypertension of various etiology
by: Yu. A. Andreeva, et al.
Published: (2008-12-01)

ANGIOTENSIN II AND MYOCARDIAL INFARCTION
by: O. P. Shevchenko, et al.
Published: (2016-01-01)

ACE Inhibitors and Angiotensin Receptor Blockers for the Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus
by: Neil Poulter
Published: (2025-02-01)

Prospects of using genetic testing to increase the effectiveness of antihypertensive therapy
by: N. V. Drobotya, et al.
Published: (2020-06-01)

ANGIOTENSIN II RECEPTOR TYPE 1 EXPRESSION IN PATIENTS WITH MULTIFOCAL ATHEROSCLEROSIS
by: I. S. Mykhailichenko
Published: (2016-04-01)

Treatment of Patients with COVID-19 and Concomitant Cardiovascular Diseases: Do not Forget About the Principles of Evidence-based Medicine
by: S. Yu. Martsevich
Published: (2020-05-01)

EFFECTS OF VITAMIN D ON THE RENIN-ANGIOTENSIN SYSTEM
by: L. Pashova-Stoyanova, et al.
Published: (2019-09-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

RAMIPRIL IN THERAPY OF PATIENTS AFTER MYOCARDIAL INFARCTION
by: I. V. Szirov, et al.
Published: (2015-12-01)

EFFICACY OF MYOCARDIAL REVASCULARIZATION IN POTENTIAL RECIPIENTS OF HEART WITH THE CHRONIC ISCHEMIC HEART FAILURE
by: S. V. Gautier, et al.
Published: (2018-04-01)

Estudio del efecto inhibitorio de extractos de Salvia scutellarioides sobre la actividad de la enzima convertidora de angiotensina
by: Gina Méndez-Callejas, et al.
Published: (2009-12-01)

View on the problem of diabetic nephropathy in children and adolescents with type 1 diabetes mellitus: the role of renin-angiotensin-aldosterone system (literature review) (part 1)
by: K. V. Skobeleva, et al.
Published: (2021-06-01)

PATIENTS WITH COMBINATION OF CHRONIC HEART FAILURE, HYPERTENSION AND HISTORY OF MYOCARDIAL INFARCTION: CLINICAL AND ANAMNESTIC CHARACTERISTICS, ADMINISTRATION OF ACE INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS, -BLOCKERS AND ADHERENCE TO THE DRUG THERAPY (DATA OF OUTPATIENT REGISTRY RECVASA)
by: M. M. Loukianov, et al.
Published: (2017-05-01)